Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors

NCT04732065 is registered in ClinicalTrials.gov with Sabine Mueller, MD, PhD as lead sponsor.

NCT NCT04732065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04732065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Phase 1 and Target Validation Study of ONC206 in Children and Young Adults With Newly Diagnosed or Recurrent Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
Lead sponsor
Sabine Mueller, MD, PhD
Phase
Phase 1
Overall status
Recruiting
Start date
August 23, 2021
Completion date
July 31, 2027
Enrollment
208 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system tumor, cns tumor, diffuse midline glioma (dmg), glioblastoma, recurrent ependymoma, recurrent malignant central nervous system neoplasm, spinal cord glioma, world health organization (who) grade iii glioma